Novartis Institutes for BioMedical Research, Inc. 3
3 · Homology Medicines, Inc. · Filed Mar 27, 2018
Insider Transaction Report
Form 3
Holdings
Series B Preferred Stock
→ Common Stock (1,979,226 underlying)
Footnotes (2)
- [F1]The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.
- [F2]The securities reported herein are held of record by Novartis Institutes for BioMedical Research, Inc. ("NIBRI"). NIBRI is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG may therefore be deemed to have or share beneficial ownership of the Series B Preferred Stock held directly by NIBRI.